Martin Wermke1, Julia Eckoldt2, Katharina S Götze3, Stefan A Klein4, Gesine Bug5, Liesbeth C de Wreede6, Michael Kramer2, Friedrich Stölzel7, Malte von Bonin8, Johannes Schetelig9, Michael Laniado10, Verena Plodeck10, Wolf-Karsten Hofmann4, Gerhard Ehninger11, Martin Bornhäuser8, Dominik Wolf12, Igor Theurl13, Uwe Platzbecker8. 1. Medizinische Fakultät Carl-Gustav-Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, University Hospital Carl-Gustav-Carus, Dresden, Germany; National Center for Tumor Diseases (NCT)-Partner Site Dresden, Dresden, Germany; Medizinische Fakultät der Technischen Universität, Universitäts KrebsCentrum, Early Clinical Trial Unit, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Germany. Electronic address: martin.wermke@ukdd.de. 2. Medizinische Fakultät Carl-Gustav-Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, University Hospital Carl-Gustav-Carus, Dresden, Germany. 3. Technische Universität München, Medizinische Klinik III, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Germany. 4. Universitätsmedizin Mannheim, Medizinische Klinik III, Mannheim, Germany. 5. Universitätsklinikum Frankfurt, Medizinische Klinik II, Frankfurt, Germany. 6. Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands; DKMS Trial Unit, Dresden, Germany. 7. Medizinische Fakultät Carl-Gustav-Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, University Hospital Carl-Gustav-Carus, Dresden, Germany; National Center for Tumor Diseases (NCT)-Partner Site Dresden, Dresden, Germany. 8. Medizinische Fakultät Carl-Gustav-Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, University Hospital Carl-Gustav-Carus, Dresden, Germany; National Center for Tumor Diseases (NCT)-Partner Site Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Germany. 9. Medizinische Fakultät Carl-Gustav-Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, University Hospital Carl-Gustav-Carus, Dresden, Germany; National Center for Tumor Diseases (NCT)-Partner Site Dresden, Dresden, Germany; DKMS Trial Unit, Dresden, Germany; DKMS gemeinnützige GmbH, Tübingen, Germany. 10. National Center for Tumor Diseases (NCT)-Partner Site Dresden, Dresden, Germany; Universitätsklinikum Carl-Gustav-Carus der Technischen Universität, Institut und Poliklinik für Radiologie, Dresden, Germany. 11. Medizinische Fakultät Carl-Gustav-Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, University Hospital Carl-Gustav-Carus, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Germany. 12. Universitätsklinikum Bonn (UKB), Medizinische Klinik 3, Onkologie, Hämatologie, Immunologie und Rheumatologie, Bonn, Germany; Universitätsklinik für Innere Medizin 5, Medical University Innsbruck, Innsbruck, Austria. 13. Medizinische Universität Innsbruck, Innere Medizin II, Innsbruck, Austria.
Abstract
BACKGROUND: The effect of systemic iron overload on outcomes after allogeneic haemopoietic cell transplantation (HCT) has been a matter of substantial debate. We aimed to investigate the predictive value of both stored (MRI-derived liver iron content) and biologically active iron (enhanced labile plasma iron; eLPI) on post-transplantation outcomes in patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogenic HCT. METHODS: The prospective, multicentre, observational, ALLogeneic Iron inVEstigators (ALLIVE) trial recruited patients at five centres in Germany. We enrolled patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogeneic HCT. Patients underwent cytotoxic conditioning for a median of 6 days (IQR 6-7) before undergoing allogeneic HCT and were followed up for up to 1 year (±3 months) post-transplantation. eLPI was measured in serum samples with the FeROS eLPI kit (Aferrix, Tel-Aviv, Israel) and values greater than 0·4 μmol/L were considered to represent raised eLPI. Liver iron content was measured by MRI. The primary endpoints were the quantitative delineation of eLPI dynamics during allogeneic HCT and the correlation coefficient between liver iron content before HCT and dynamic eLPI (eLPIdyn; maximum eLPI minus baseline eLPI). All patients with available data were included in all analyses. This is the final analysis of this completed trial, which is registered with ClinicalTrials.gov, number NCT01746147. FINDINGS: Between Dec 13, 2012, and Dec 23, 2014, 112 patients underwent allogeneic HCT. Liver iron content before allogeneic HCT was not significantly correlated with eLPIdyn (ρ=0·116, p=0·22). Serum eLPI concentrations rapidly increased during conditioning, and most (79 [73%] of 108) patients had raised eLPI by the day of transplantation. Patients with a pretransplant liver iron content greater than or equal to 125 μmol/g had an increased incidence of non-relapse mortality (20%, 95% CI 14-26) compared with those with lower concentrations (7%, 2-12; p=0·039) at day 100. Patients who had raised eLPI at baseline also had a significantly increased incidence of non-relapse mortality at day 100 (33%, 15-52) compared with those who had normal eLPI at baseline (7%, 2-13; p=0·00034). INTERPRETATION: eLPI is a possible biological mediator of iron-related toxicity. Peritransplantation eLPI-scavenging strategies could be explored in prospective interventional clinical trials for patients with systemic iron overload. FUNDING: The Technical University of Dresden and Novartis.
BACKGROUND: The effect of systemic iron overload on outcomes after allogeneic haemopoietic cell transplantation (HCT) has been a matter of substantial debate. We aimed to investigate the predictive value of both stored (MRI-derived liver iron content) and biologically active iron (enhanced labile plasma iron; eLPI) on post-transplantation outcomes in patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogenic HCT. METHODS: The prospective, multicentre, observational, ALLogeneic Iron inVEstigators (ALLIVE) trial recruited patients at five centres in Germany. We enrolled patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogeneic HCT. Patients underwent cytotoxic conditioning for a median of 6 days (IQR 6-7) before undergoing allogeneic HCT and were followed up for up to 1 year (±3 months) post-transplantation. eLPI was measured in serum samples with the FeROS eLPI kit (Aferrix, Tel-Aviv, Israel) and values greater than 0·4 μmol/L were considered to represent raised eLPI. Liver iron content was measured by MRI. The primary endpoints were the quantitative delineation of eLPI dynamics during allogeneic HCT and the correlation coefficient between liver iron content before HCT and dynamic eLPI (eLPIdyn; maximum eLPI minus baseline eLPI). All patients with available data were included in all analyses. This is the final analysis of this completed trial, which is registered with ClinicalTrials.gov, number NCT01746147. FINDINGS: Between Dec 13, 2012, and Dec 23, 2014, 112 patients underwent allogeneic HCT. Liver iron content before allogeneic HCT was not significantly correlated with eLPIdyn (ρ=0·116, p=0·22). Serum eLPI concentrations rapidly increased during conditioning, and most (79 [73%] of 108) patients had raised eLPI by the day of transplantation. Patients with a pretransplant liver iron content greater than or equal to 125 μmol/g had an increased incidence of non-relapse mortality (20%, 95% CI 14-26) compared with those with lower concentrations (7%, 2-12; p=0·039) at day 100. Patients who had raised eLPI at baseline also had a significantly increased incidence of non-relapse mortality at day 100 (33%, 15-52) compared with those who had normal eLPI at baseline (7%, 2-13; p=0·00034). INTERPRETATION: eLPI is a possible biological mediator of iron-related toxicity. Peritransplantation eLPI-scavenging strategies could be explored in prospective interventional clinical trials for patients with systemic iron overload. FUNDING: The Technical University of Dresden and Novartis.
Authors: Anna-Maria Dietl; Matthias Misslinger; Mario M Aguiar; Vasyl Ivashov; David Teis; Joachim Pfister; Clemens Decristoforo; Martin Hermann; Sean M Sullivan; Larry R Smith; Hubertus Haas Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Olaf Penack; Christophe Peczynski; Steffie van der Werf; Jürgen Finke; Arnold Ganser; Helene Schoemans; Jiri Pavlu; Riitta Niittyvuopio; Wilfried Schroyens; Leylagül Kaynar; Igor W Blau; Walter J F M van der Velden; Jorge Sierra; Agostino Cortelezzi; Gerald Wulf; Pascal Turlure; Montserrat Rovira; Zubeydenur Ozkurt; Maria J Pascual-Cascon; Maria C Moreira; Johannes Clausen; Hildegard Greinix; Rafael F Duarte; Grzegorz W Basak Journal: Front Immunol Date: 2020-04-15 Impact factor: 7.561
Authors: Marlijn Hoeks; Ge Yu; Saskia Langemeijer; Simon Crouch; Louise de Swart; Pierre Fenaux; Argiris Symeonidis; Jaroslav Čermák; Eva Hellström-Lindberg; Guillermo Sanz; Reinhard Stauder; Mette Skov Holm; Moshe Mittelman; Krzysztof Mądry; Luca Malcovati; Aurelia Tatic; Antonio Medina Almeida; Ulrich Germing; Aleksandar Savic; Njetočka Gredelj Šimec; Dominic Culligan; Raphael Itzykson; Agnes Guerci-Bresler; Borhane Slama; Jackie Droste; Corine van Marrewijk; Arjan van de Loosdrecht; Nicole Blijlevens; Marian van Kraaij; David Bowen; Theo de Witte; Alex Smith Journal: Haematologica Date: 2019-07-05 Impact factor: 9.941